middle.news
How Will Botanix’s US$30M Debt Facility Accelerate Sofdra™ Commercialisation?
8:59am on Tuesday 10th of June, 2025 AEST
•
Healthcare
Read Story
How Will Botanix’s US$30M Debt Facility Accelerate Sofdra™ Commercialisation?
8:59am on Tuesday 10th of June, 2025 AEST
Key Points
US$30 million (~A$48 million) debt facility arranged with Kreos Capital
Facility split into two tranches, US$20 million available immediately, US$10 million by October 2026
Loan secured against Botanix’s assets with warrants issued to Kreos Capital
Complements recent A$40 million capital raising and ~A$28 million cash on hand
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE